ABBOTINDIA:NSE-Abbott India Limited (INR)

COMMON STOCK | Drug Manufacturers—General | NSE

Last Closing Price

INR 15,451.10

Change

+240.65 (+1.58)%

Market Cap

INR 322.90B

Volume

0.02M

Average Target Price

INR 14,600.00 (-5.51%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolics, central nervous system, pain management, nutritional supplements, vitamins, insomnia, vaccines, consumer health, etc. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. Abbott India Limited was founded in 1944 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Laboratories

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-31 )

Largest Industry Peers for Drug Manufacturers—General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CIPLA:NSE Cipla Limited

-8.90 (-2.06%)

INR341.19B 20.46 9.70
GLAXO:NSE GlaxoSmithKline Pharmaceutical..

+30.10 (+2.45%)

INR199.35B 195.97 30.73
PFIZER:NSE Pfizer Limited

+155.05 (+4.01%)

INR176.17B 34.17 25.49
SANOFI:NSE Sanofi India Limited

-2.85 (-0.05%)

INR143.10B 34.77 19.94
MARKSANS:NSE Marksans Pharma Limited

+0.50 (+3.73%)

INR5.69B 6.41 4.32
SMSPHARMA:NSE SMS Pharmaceuticals Limited

+0.45 (+1.70%)

INR2.21B 5.71 4.44
KILITCH:NSE Kilitch Drugs (India) Limited

+2.40 (+3.02%)

INR1.27B 48.84 16.35
KOPRAN:NSE Kopran Limited

+2.75 (+12.14%)

INR1.10B 4.60 4.54

ETFs Containing ABBOTINDIA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.59% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.59% 100% A+ 98% A+
Trailing 12 Months  
Capital Gain 111.75% 100% A+ 100% A+
Dividend Return 0.69% 75% C 40% F
Total Return 112.44% 100% A+ 100% A+
Trailing 5 Years  
Capital Gain 288.10% 100% A+ 98% A+
Dividend Return 5.17% 75% C 48% F
Total Return 293.27% 100% A+ 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 25.46% 83% B 77% C+
Dividend Return 0.80% 64% D 56% F
Total Return 26.26% 83% B 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 32.85% 42% F 64% D
Risk Adjusted Return 79.95% 83% B 92% A-
Market Capitalization 322.90B 89% B+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 54.31 22% F 6% F
Price/Book Ratio 15.16 11% F 1% F
Price / Cash Flow Ratio 64.69 33% F 3% F
EV/EBITDA 41.17 11% F 4% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 18.57% 100% A+ 84% B
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.18 100% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.